A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs EYP 001 (Primary) ; Entecavir; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors ENYO Pharma
- 27 Feb 2018 According to an ENYO Pharma media release, resuts are expected in in Q2 2018.
- 20 Oct 2017 Status changed from not yet recruiting to recruiting.
- 28 Dec 2016 New trial record